Low-dose Pimecrolimus, an FDA-approved Calcineurin Inhibitor, Sensitizes Drug-resistant Cancer Cells < em > via < /em > Strong P-gp Inhibition

CONCLUSION: PIME, currently used in clinics, can be repositioned for treating patients with P-gp-over-expressing resistant cancer (stem) cells.PMID:36854528 | DOI:10.21873/anticanres.16255

Source: Cell Research - February 28, 2023 Category: Cytology Authors: Jae Hyeon Park Ji Sun Lee Joo Kyung Shin Swati Sharma Hyung Sik Kim Sungpil Yoon Source Type: research